Dolomite Microfluidics launches Automated Nanoparticle System for formulation library generation
Dolomite Microfluidics is leading the way in nanoparticle production with the release of its innovative Automated Nanoparticle (ANP) System for microfluidic formulation library generation This next generation automated platform is the result of a four-year focus on the challenges commonly associated with batch production of lipid nanoparticles and liposomes for drug and vaccine development, including inconsistent particle size and poor encapsulation efficiency.
Liposomes and lipid nanoparticles are becoming increasingly important in a wide range of industries, particularly pharmaceuticals, where they can be used as drug delivery vehicles or to encapsulate vaccines, including for COVID-19. The ANP System will provide researchers with a tool for more efficient and cost-effective protocol development, offering an alternative to commonly used IP licensing models for library creation and freeing up time for other lab processes.
The modular ANP System is designed to fill a gap in the marketplace for customers wanting to progress through the protocol development pipeline without changing their system entirely, or to generate nanoparticles at small scale using reduced quantities of precious cargo. Its microfluidic approach allows rapid and reproducible generation of highly monodisperse particles from 40 to 800 nm, with enhanced encapsulation efficiency. Lipid solutions and cargoes are loaded directly into sample loops, automatically injected into the system, and the resulting liposomes are collected in individual vials to avoid cross-contamination. The ANP System is available for process optimization and fully automated for walk-away library generation.
Richard Gray, Commercial Director at Dolomite Microfluidics, commented: “The launch of our Automated Nanoparticle System for formulation library generation will help to meet the huge demand for consistent lipid nanoparticle and liposome preparation. The system offers the flexibility to test many different parameters for protocol development and optimization, and can be tailored to individual needs, including process scale-up.”
Find out more about microfluidic methods to accelerate vaccine R&D and production: